Stock Scorecard
Stock Summary for Collegium Pharmaceutical Inc (COLL) - $40.91 as of 3/28/2024 3:50:41 PM EST
Total Score
14 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for COLL
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for COLL
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for COLL
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for COLL
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for COLL
Financial Details for COLL
Company Overview |
|
---|---|
Ticker | COLL |
Company Name | Collegium Pharmaceutical Inc |
Country | USA |
Description | Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/2/2024 |
Stock Price History |
|
Last Day Price | 40.91 |
Last Day Price Updated | 3/28/2024 3:50:41 PM EST |
Last Day Volume | 362,415 |
Average Daily Volume | 512,873 |
52-Week High | 40.91 |
52-Week Low | 20.83 |
Last Price to 52 Week Low | 96.40% |
Valuation Measures |
|
Trailing PE | 31.52 |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | 22.30 |
Free Cash Flow Ratio | 3.38 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 1.17 |
Total Cash Per Share | 12.11 |
Book Value Per Share Most Recent Quarter | 6.13 |
Price to Book Ratio | 6.53 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 2.29 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 31,959,800 |
Market Capitalization | 1,307,475,418 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 5,198.00% |
Annual Earnings Growth | 292.60% |
Reported EPS 12 Trailing Months | 1.29 |
Reported EPS Past Year | 1.18 |
Reported EPS Prior Year | 0.56 |
Net Income Twelve Trailing Months | 48,155,000 |
Net Income Past Year | 48,155,000 |
Net Income Prior Year | -25,002,000 |
Quarterly Revenue Growth YOY | 15.50% |
5-Year Revenue Growth | -3.18% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 386,878,000 |
Total Cash Past Year | 386,878,000 |
Total Cash Prior Year | 173,688,000 |
Net Cash Position Most Recent Quarter | -280,293,000 |
Net Cash Position Past Year | -280,293,000 |
Long Term Debt Past Year | 667,171,000 |
Long Term Debt Prior Year | 700,951,000 |
Total Debt Most Recent Quarter | 667,171,000 |
Equity to Debt Ratio Past Year | 0.23 |
Equity to Debt Ratio Most Recent Quarter | 0.23 |
Total Stockholder Equity Past Year | 195,431,000 |
Total Stockholder Equity Prior Year | 194,842,000 |
Total Stockholder Equity Most Recent Quarter | 195,431,000 |
Options |
|
Put/Call Ratio | 0.08 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 1.34 |
MACD Signal | 1.26 |
20-Day Bollinger Lower Band | 23.73 |
20-Day Bollinger Middle Band | 32.73 |
20-Day Bollinger Upper Band | 41.72 |
Beta | 1.01 |
RSI | 66.33 |
50-Day SMA | 26.40 |
200-Day SMA | 21.97 |
System |
|
Modified | 3/27/2024 9:46:26 PM EST |